These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 28898890)

  • 1. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
    Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW
    Respiration; 2017; 94(5):408-415. PubMed ID: 28898890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002).
    Gotfried MH; Girod CE; Antin-Ozerkis D; Burgess T; Strombom I; Stauffer JL; Kirchgaessler KU; Padilla ML
    Pulm Ther; 2018 Jun; 4(1):59-71. PubMed ID: 32026243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.
    Valeyre D; Albera C; Bradford WZ; Costabel U; King TE; Leff JA; Noble PW; Sahn SA; du Bois RM
    Respirology; 2014 Jul; 19(5):740-7. PubMed ID: 24836849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
    Costabel U; Albera C; Bradford WZ; Hormel P; King TE; Noble PW; Sahn SA; Valeyre D; du Bois RM
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):198-205. PubMed ID: 25363219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies.
    Behr J; Nathan SD; Costabel U; Albera C; Wuyts WA; Glassberg MK; Haller H; Alvaro G; Gilberg F; Samara K; Lancaster L
    Adv Ther; 2023 Sep; 40(9):3937-3955. PubMed ID: 37391667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.
    Lancaster L; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; King TE; Lederer DJ; Lin Z; Nathan SD; Pereira CA; Swigris JJ; Valeyre D; Noble PW
    BMJ Open Respir Res; 2016; 3(1):e000105. PubMed ID: 26835133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
    Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
    Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.
    Costabel U; Albera C; Glassberg MK; Lancaster LH; Wuyts WA; Petzinger U; Gilberg F; Kirchgaessler KU; Noble PW
    Respir Res; 2019 Mar; 20(1):55. PubMed ID: 30866942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis.
    Marcos Ribes B; Sancho-Chust JN; Talens A; Arlandis M; Herraiz P; Chiner E; Aznar T
    Eur J Hosp Pharm; 2020 Nov; 27(6):350-354. PubMed ID: 33020058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
    Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT.
    Jouneau S; Gamez AS; Traclet J; Nunes H; Marchand-Adam S; Kessler R; Israël-Biet D; Borie R; Strombom I; Scalori A; Crestani B; Valeyre D; Cottin V
    Respiration; 2019; 98(1):19-28. PubMed ID: 30965332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.
    Wijsenbeek MS; Grutters JC; Wuyts WA
    Adv Ther; 2015 Jul; 32(7):691-704. PubMed ID: 26173796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
    Nathan SD; Albera C; Bradford WZ; Costabel U; Glaspole I; Glassberg MK; Kardatzke DR; Daigl M; Kirchgaessler KU; Lancaster LH; Lederer DJ; Pereira CA; Swigris JJ; Valeyre D; Noble PW
    Lancet Respir Med; 2017 Jan; 5(1):33-41. PubMed ID: 27876247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
    Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
    Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis.
    Yoon HY; Kim DS; Song JW
    Respiration; 2019; 97(3):242-251. PubMed ID: 30332670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.
    Dhooria S; Agarwal R; Sehgal IS; Prasad KT; Muth V; Garg M; Bal A; Aggarwal AN; Behera D
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):148-157. PubMed ID: 33093778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.